Introduction {#s1}
============

Primary immunodeficiencies (PIDs) are a phenotypically and genetically heterogeneous group of more than 300 monogenic inherited disorders resulting in immune defects that predispose patients to infections, autoimmune disorders, lymphoproliferative disease, and malignancies ([@B1]--[@B3]). PIDs with a more severe phenotype lead to life-threatening infections and life-limiting complications that require a prompt and accurate diagnosis in order to initiate lifesaving therapy ([@B4], [@B5]). Phenotypic and genotypic heterogeneity of PIDs make genetic diagnosis often complex and delayed. Indeed, more than one genotype might cause similar clinical phenotypes, but identical genotypes will not often produce the same phenotype and finally clinical penetrance may be different ([@B6]--[@B9]). The characterization of PID-associated genes is expected to significantly contribute to define the molecular events governing immune system development and will provide new insights into the pathogenesis of PIDs. Molecular genetic testing is also a useful tool for the diagnosis of PIDs in atypical cases ([@B6], [@B10]).

Despite the progress in the genetic characterization of PIDs, many patients still lack a molecular diagnosis. A better understanding of the genetic and immune defects of patients is critical to develop therapeutic strategies aimed at changing the clinical course of the disease and to guarantee an appropriate genetic counseling allowing the identification of PID patients before the onset of the disease ([@B11]--[@B13]). The application of Next Generation Sequencing (NGS) to PIDs has been a revolution and it has accelerated the discovery and identification of novel disease-causing genes and the genetic diagnosis of patients with monogenic inborn errors of immunity ([@B7], [@B8], [@B14]--[@B16]). Targeted gene-panel sequencing ([@B17]--[@B21]), whole exome sequencing (WES) ([@B22], [@B23]) or whole genome sequencing (WGS) ([@B24]) approaches can rapidly identify candidate gene variants in an increasing number of genetically undefined diseases ([@B17], [@B24]) and are widely used in several laboratories for the diagnosis of PIDs ([@B10]). WGS also offers the opportunity to find causative variants in the structural regions of a given gene. These tools increase the amount of data analysis that can identify causative genes in both clinically defined and atypical diseases. Nonetheless, delay in diagnosis can be caused by the huge amount of data retrieved from whole sequencing, increased costs sustained by clinical laboratories and the requirement of trained personnel to validate variants ([@B7], [@B8], [@B22]). An increased depth of the sequencing coverage is generally obtained using targeted gene panels, in favor of a high accuracy, amelioration of sensitivity and management of datasets, reducing the time of analysis, the costs and the interpretation of results, thus accelerating the diagnosis for the majority of PIDs ([@B14], [@B16]--[@B18]). On the other hand, the usefulness of targeted exome sequencing approach for the identification of PID patients has been demonstrated, with accurate detection of point mutations and exonic deletions in patients with either known or unknown genetic diagnosis ([@B7], [@B8]).

In this study, we report the clinical and molecular characterization of 105 PID patients presenting with either typical SCID/CID or with overlapping PID phenotypes. Differently from other studies ([@B20], [@B21], [@B25]), most patients enrolled in this work had non-consanguineous parents. Two targeted sequencing approaches were compared to test the ion torrent reliability in diagnostics and Haloplex Target Enrichment System in diagnostics and for research purposes. **Three** diagnostic panels including known disease genes had been developed for the Ion Torrent platform (ThermoFisher). The Haloplex panels comprised well-defined PID genes (\>300) and candidate genes associated with PIDs due to their expression and function in critical immune-pathways ([@B1], [@B3]). This work underlines how targeted NGS panels allow a high-throughput low-cost pipeline to identify the molecular bases of PIDs and are sensitive and accurate diagnostic tools for simultaneous mutation screening of known or putative PID-related genes.

Materials and Methods {#s2}
=====================

Patients
--------

We report the clinical and molecular characterization of 105 PID patients mainly referred to three centers (2 in Rome and 1 in Milan) participating in the Italian network of PIDs (IPINET) and part of The European Reference Network on immunodeficiency, autoinflammatory, and autoimmune diseases (ERN RITA). Nine of these patients have been enrolled in the pCID study (DRKS00000497). Data were obtained from year 2014 to 2017.

Ion Torrent and/or Haloplex panels were applied for the analysis of samples and compared. Six patients previously diagnosed by Sanger sequencing were included in the study (**Table 2A**) as internal positive controls. The Ion Torrent panels were used for the analysis of 73 patients with suspicion of PID. Among this group, 18 patients, still remaining without a molecular diagnosis and 32 additional patients, were tested by Haloplex panels (Target Enrichment System for Illumina platform). The work was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent, approved by the Ethical Committee of the Children\'s Hospital Bambino Gesù, San Raffaele Hospital (TIGET06, TIGET09) and Policlinico Tor Vergata, was obtained from either patients or their parents/legal guardians, if minors. Patients and their clinical and immunological features are reported in [Table 1](#T1){ref-type="table"}.

###### 

Clinical, immunological and molecular features of PID patients.

  **PID ID**   **AGE AT PRESENTATION**   **GENDER**   **ADMITTING CLINICAL DIAGNOSIS**         **NGS PLATFORM**                            **GENETIC DIAGNOSIS**   **NEUTRAL VARIANTS AND VUS**                         **OPPORTUNISTIC/RECURRENT INFECTIONS**                                                                                     **IMMUNEDYSREGULATION/ MALIGNANCIES/ OTHERS**                                                                                         **IMMUNOPHENOTYPE**
  ------------ ------------------------- ------------ ---------------------------------------- ------------------------------------------- ----------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  PID 1        BIRTH                     M            OMENN SYNDROME                           ION TORRENT PANEL 1                         ***RAG1***                                                                   CHRONIC CMV VIREMIA, PNEUMOCYSTOSIS, HERPETIC KERATITIS                                                                    TUBULE INTERSTITIAL NEPHRITIS WITH LYMPHO-MONOCYTE INFILTRATE                                                                         T+, B-, NK+
  PID 2        2 mo                      M            SCID                                     ION TORRENT PANEL 1                         ***RAG2***                                                                   EBV AND ADENOVIRUS POST HSCT                                                                                                                                                                                                                                     T+ (↓CD4 , ↓CD8), B-, ↑NK, ↓IgM, ↓IgA
  PID 3        5 mo                      F            SCID                                     ION TORRENT PANEL 1                         ***RAG2***                                                                   ADENOVIRUS                                                                                                                                                                                                                                                       T-, B-, NK+
  PID 4        2mo                       M            SCID                                     ION TORRENT PANEL 1                         ***RAG1***                                                                   CHRONIC CMV VIREMIA                                                                                                                                                                                                                                              T+, B-, NK+, ↓IgM
  PID 5        5mo                       M            SCID                                     ION TORRENT PANEL 1                         ***IL2RG***                                                                  ADENOVIRUS, HEPATITIS, ENTEROBACTHER CLOACAE; CANDIDA                                                                      DERMATITIS (BOLLOUS TYPE)                                                                                                             T-, B-,↑NK
  PID 6        4mo                       M            SCID                                     ION TORRENT PANEL 1                         ***JAK3***                                                                   INTERSTITIAL PNEUMONIA, PNEUMOCYSTOSIS                                                                                                                                                                                                                           T-, B+, NK-, HYPGAMMAGLOBULINEMIA
  PID 7        4mo                       M            SCID                                     ION TORRENT PANEL 1-2                                                                                                    INTERSTITIAL LUNG DISEASE; URI; LRI                                                                                        HEPATOSPLENOMEGALY, AIHA, ITP                                                                                                         T+ (ABSENT NAIVE and RTE, ↑γδ), B+, NK+
  PID 8        1 y                       M            SCID                                     ION TORRENT PANEL 1-2                                                                                                                                                                                                                               HEPATOSPLENOMEGALY, AIHA, ITP, VERTEBRAL WEDGING AND OSTEOPENIA                                                                       T (ABSENT NAIVE and RTE, ↑γδ), B+(↑UNSWITCHED MEMORY), NK+
  PID 9        9mo                       F            SCID                                     ION TORRENT PANEL 1-2                                                                                                    GLUTEAL ABSCESS                                                                                                            CHRONIC DIARRHEA                                                                                                                      T+ (↑CM CD4 , ↑γδ), B-, NK-
  PID 10       2mo                       F            SCID                                     ION TORRENT PANEL 1-2                                                                                                    POST-NATAL CMV INFECTION; URI;LRI; NEONATAL SEPSIS                                                                                                                                                                                                               T+, B (ABSENT SWITCHED MEMORY), NK+
  PID 11       na                        F            SCID                                     ION TORRENT PANEL 1-2                                                                                                    CHRONIC VZV VIREMIA                                                                                                        THROMBOCYTOPENIA                                                                                                                      T- (↓ CD4), B+, NK+
  PID 12       1y                        M            SCID                                     ION TORRENT PANEL 1-2/ HALOPLEX PANEL 2     ***ADA***                                                                    URI                                                                                                                                                                                                                                                              T-, B-, NK+
  PID 13       2y                        M            SCID                                     ION TORRENT PANEL 1-2/ HALOPLEX PANEL 2                             *CECR1*                                              PENUMONIA; CANDIDIASIS                                                                                                     GASTROENTERITIS, HyperIgE; LYELL SYNDROME, CARDIAC ARREST OF UNKNOWN ORIGIN; ILEOILEAL INTUSSUSCEPTION                                LOW T, B-, ↑NK+, ↑IgM, ↓IgA, ↑IgE
  PID 14       5mo                       M            SCID                                     ION TORRENT PANEL 1-2                                                                                                    CHRONIC CMV AND EBV VIREMIA                                                                                                                                                                                                                                      ↓T (ABSENT NAIVE CD4 and CD8, ↑γδ), B+, ↑NK
  PID 15       1y                        F            SCID                                     ION TORRENT PANEL 1-2                       ***ADA***                                                                    LRI                                                                                                                                                                                                                                                              T-, B-, NK+, ↓IgM
  PID 16       8 mo                      M            leaky SCID                               ION TORRENT PANEL 1-2                       ***IL2RG***                                                                  CHRONIC CMV VIREMIA, SEVERE CMV INTERSTITIAL PNEUMONIA                                                                     PNEUMONIA, DERMATITIS, GROWTH FAILURE                                                                                                 T+/-, B-, NK+
  PID 17       1y                        M            SCID                                     ION TORRENT PANEL 1                         ***IL2RG***                                                                  CHRONIC CMV VIREMIA, BRONCHIOLITIS, UTI, ROTAVIRUS ENTERITIS                                                               HEPATOSPLENOMEGALY, HLH                                                                                                               ↓T (ABSENT NAIVE CD4 and CD8), B-, NK+
  PID 18       4d (DIED)                 M            SCID                                     ION TORRENT PANEL 1                         ***IL2RG***                                                                  CMV, PNEUMOCYSTIS JIROVECI PNEUMONIA                                                                                                                                                                                                                             T-, B+, ↓NK
  PID 19       5mo                       M            SCID                                     ION TORRENT PANEL 1                         ***IL2RG***                                                                  STAPHYLOCOCCUS HAEMOLYTICUS; ASPERGILLUS, BCGITIS                                                                                                                                                                                                                T-, ↑B+, ↓NK+, ↓IgM, ↓IgA
  PID 20       1.8y                      F            SCID                                     ION TORRENT PANEL 1-2                       ***RAG1***                                                                   LTI                                                                                                                        HEPATOSPLENOMEGALY                                                                                                                    T-, B-, NK+, ↑IgG, ↓IgM, ↓IgA, ↓IgE
  PID 21       1y                        M            SCID                                     ION TORRENT PANEL 1-2                       ***CD3D***                                                                   RHINOVIRUS, MYCOBACTERIUM                                                                                                                                                                                                                                        T (↓NAIVE CD4, ABSENT CD8, ↑γδ), B+, NK+
  PID 22       1.3y                      M            SCID                                     ION TORRENT PANEL 1                         ***RAG1***                                                                   LRI, ADENOVIRUS, ROTAVIRUS ENTERITIS, PSEUDOMONAS AERUGINOSA                                                                                                                                                                                                     T-, B-, NK+, ↓IgM, ↓IgA, ↓IgE
  PID 23       11mo                      F            SCID                                     ION TORRENT PANEL 1                         ***JAK3***                                                                   CHRONIC HHV-6 VIREMIA, CANDIDA ALBICANS, ROTAVIRUS, CORONAVIRUS 229E,                                                                                                                                                                                            T-, B+, ↑NK, ↓IgG, ↓IgM, ↓IgA
  PID 24       4mo                       F            SCID                                     ION TORRENT PANEL 1                         ***JAK3***                                                                   LRI, CANDIDA ALBICANS, RHINOVIRUS                                                                                                                                                                                                                                T-, B+, ↑NK, ↓IgE
  PID 25       na                        M            SCID                                     HALOPLEX PANEL 1                            ***IL7R***                                                                   na                                                                                                                         na                                                                                                                                    T-, B+, NK+
  PID 26       1y                        M            CID                                      HALOPLEX PANEL 1                                                                                                                                                                                                                                    AIHA                                                                                                                                  T-, B-, NK+, ↓IgM, ↓IgA
  PID 27       5                         F            CID                                      ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1                                                                                  IR, EPIDERMODYSPLASIA VERRUCIFORMIS (HPV-8 WARTS); URI                                                                     MILD MYELODYSPLASIA, SEVERE HEPATIC STEATOSIS                                                                                         T (↓NAIVE and ↓RTE), B+, NK+
  PID 28       3                         F            CID                                      ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1                                                                                  CHRONIC EBV VIREMIA, URI, PNEUMONIA                                                                                        ENTEROPATHY; CHRONIC-PANCREATITIS; ANA/ANCA+                                                                                          T (↓NAIVE), B+, NK+
  PID 29       1 y                       M            CID                                      ION TORRENT PANEL 1                         ***RAG1***                                                                   CHRONIC CMV AND EBV VIREMIA, HAEMOPHILUS INFLUENZAE AND BOCAVIRUS RESPIRATORY INFECTION, LONG-LASTING ROTAVIRUS DIARRHEA   THROMBOCYTOPENIA, AHIA , SEVERE HEPATOSPLENOMEGALY, WITH LIVER FAILURE                                                                ↓T, B+, NK+, ↑IgE, ↑IgM, ↑IgG
  PID 30       3                         M            CID                                      ION TORRENT PANEL 1-2                                                                                                    URI                                                                                                                        DERMATITIS; ANA+                                                                                                                      ↓T (↓NAIVE CD4), B+, NK+
  PID 31       3                         F            CID                                      ION TORRENT PANEL 1                         ***RAG1***                                                                   CHRONIC HHV-6, CMV,EBV VIREMIA; URI, LRI                                                                                   AHIA                                                                                                                                  T+, ↓ B, NK+, ↓IgM, ↓IgA
  PID 32       3y                        F            CID                                      ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1                                                                                  CHRONIC EBV VIREMIA, URI                                                                                                   HODGKIN LYMPHOMA; ENTEROPATHY                                                                                                         T (↓NAIVE), B-, NK+
  PID 33       10y                       M            CID                                      ION TORRENT PANEL 2                                                                                                      CHRONIC EBV VIREMIA, URI-LRI                                                                                               LYMPHADENOPATHY, URTICARIA, LONG-COURSE DIARROHEA /LYMPHATIC HYPERPLASIA                                                              T+, B-, NK+
  PID 34       1y                        F            CID                                      ION TORRENT PANEL 1                                                                                                                                                                                                                                 SEVERE DERMATITIS, DIARRHEA, INTERSTITIOPATHY                                                                                         T (↓CD8), ↑B+, NK+
  PID 35       11y                       F            CID                                      HALOPLEX PANEL 1                                                                                                                                                                                                                                    COLITIS, GH DEFICIENCY                                                                                                                LYMPHOPENIA, ↓T, ↓B, ↓NK (UNDER AZA)
  PID 36       15 mo                     F            CID                                      ION TORRENT PANEL 1-2                       ***IL7R***                                                                   CHRONIC EBV VIREMIA, URI (recurrent)                                                                                       THROMBOCYTOPENIA,SEVERE DERMATITIS, GROWTH RETARDATION,                                                                               HYPERGAMMAGLOBULINEMIA (maternal engraftment)
  PID 37       1mo                       M            CID                                      HALOPLEX PANEL 2                            ***ARPC1B***                                                                 WARTS, RECURRENT INFECTIONS                                                                                                VASCULITIS, LYMPHADENOPATHY, ECZEMA, HYPOGAMMAGLOBULINEMIA, HYPER IgE, THROMBOCYTOPENIA, LUNG DISEASE, BRONCHIECTASIS                 ↓T, B+, ↓NK, ↓IgG , ↓IgM, ↑IgA, ↑IgE
  PID 38       0.8y                      M            CID                                      HALOPLEX PANEL 2                                                    *NFKB1*                                              RECURRENT ESOPHAGEAL CANDIDIASIS, LUNG ABSCESS                                                                             ESOPHAGEAL ATRESIA                                                                                                                    T+, B+, NK+
  PID 39       13 mo                     F            CID                                      HALOPLEX PANEL 1                            ***RAG1***                                                                   RECURRENT BRONCHITIS                                                                                                       SEVERE AUTOIMMUNE HEMOLITIC ANEMIA, INTERSTITIAL PNEUMOPATHY AND BRONCHIECTASIS                                                       T+, B+, NK+
  PID 40       na (adopted 11y)          F            CID                                      HALOPLEX PANEL 1                                                                                                         RECURRENT HERPETIC INFECTIONS (STOMATITIS)                                                                                                                                                                                                                       ↓T, ↓B, NK+
  PID 41       18 mo                     F            CID                                      HALOPLEX PANEL 1                                                                                                         RECURRENT RESPIRATORY INFECTIONS AND OTITIS, POSITIVE HCV                                                                  HODGKIN LYMPHOMA, OBSTRUCTIVE LUNG DISEASE                                                                                            ↓T (↓CD4), B-, ↑IgM, ↓IgG, ↓IgA
  PID 42       1d                        F            SYNDROMIC T-CELL DEFECT                  ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1                                                                                  POST SURGICAL SEPSIS                                                                                                       CHDs, OSTEOMYELITIS                                                                                                                   T-, B+, NK+
  PID 43       8y                        M            SYNDROMIC T-CELL DEFECT                  ION TORRENT PANEL 1-2                                                                                                    URI, NEONATLA SEPSIS                                                                                                       ATOPY, CHDs                                                                                                                           T+, B-, NK+
  PID 44       4y                        M            SYNDROMIC T-CELL DEFECT                  ION TORRENT 1-2/ HALOPLEX PANEL 1                                                                                        URI; SINUSITIS                                                                                                             MALFORMATIVE SYNDROME; PSYCHOMOTOR RETARDATION                                                                                        T+, ↓B, NK+
  PID 45       13y                       M            UNCLASSIFIED T-CELL DEFICIENCY           ION TORRENT PANEL 2/HALOPLEX PANEL 2                                                                                     CHRONIC EBV VIREMIA, PNEUMONIA                                                                                             HEPATOSPLENOMEGALY, LYMPHOADENOPATY; NEPHROTIC SYNDROME                                                                               T (↓NAIVE CD4, CD8, RTE), ↓B, NK+, ↑IgM, ↓IgA
  PID 46       3y                        M            UNCLASSIFIED T-CELL DEFICIENCY           ION TORRENT PANEL 1-2/HALOPLEX PANEL 1                                                                                   CHRONIC EBV VIREMIA, URI, LRI                                                                                              PULMONARY NLH                                                                                                                         T (↓NAIVE CD4, AND CD8), ↑B, ↑NK
  PID 47       8y                        M            UNCLASSIFIED T-CELL DEFICIENCY           ION TORRENT PANEL 1-2                                                                                                    CHRONIC EBV VIREMIA, URI, UTI                                                                                              GASTROENTERITIS, ATOPIC DERMATITIS                                                                                                    T+ (↑CD4 CM) B+ NK+
  PID 48       5y                        M            UNCLASSIFIED T-CELL DEFICIENCY           ION TORRENT PANEL 1-2                                                                                                                                                                                                                               AIHA; VASCULITIS, APHTOSIS                                                                                                            T (↓CD4) ↓B+ ↑NK
  PID 49       6y                        M            HIGM                                     ION TORRENT PANEL 1-2                       ***CD40LG***                                                                 CRYPTOSPORIDIUM                                                                                                            CHRONIC GASTRITIS,SCLEROSIS CHOLANGITIS                                                                                               T+, B+(↓ SWITCHED MEMORY), NK+
  PID 50       2y                        M            HIGM                                     ION TORRENT PANEL 1                                                 *CD40LG*                                             CHRONIC EBV VIREMIA                                                                                                        NEPHROTIC SYNDROME,PSYCHOMOTOR DELAY, LEUKODYSTROPHY                                                                                  T+ (↑CD8 EM), B+(↓ SWITCHED MEMORY), NK+
  PID 51       10y                       M            AGAMMAGLOBULINEMIA                       ION TORRENT PANEL 1 HALOPLEX PANEL 1        ***RAG1***                                                                   CHRONIC EBV VIREMIA, URI                                                                                                   NASAL POLYPOSIS, CHRONIC BRONCOPNEUMOPATHY                                                                                            T+, VERY ↓B, NK+, ↓IgM, ↓IgG, ↓IgA
  PID 52       14y                       M            CVID                                     ION TORRENT PANEL 1-2-3/ HALOPLEX PANEL 2                                                                                URI, PNEUMONIA                                                                                                             CHRONIC BRONCOPNEUNOPATY, BRONCHIECTASIS, GROWTH RETARDATION                                                                          T+(↓ NAIVE CD4 and CD8), ↓B (↓ SWITCHED MEMORY) , NK+, ↓IgM, ↓IgG, ↓IgA
  PID 53       1y                        F            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                  UTI, PNEUMONIA                                                                                                             ATOPY                                                                                                                                 T+ (↑CD8 EM EMRA), ↓B (↓ SWITCHED MEMORY) , NK+, ↓IgG, ↓IgA
  PID 54       5y                        F            CVID                                     ION TORRENT PANEL 1-2-3                                             *PLCG2*                                              URI, PARASITE INFECTION (OXYURIASIS)                                                                                                                                                                                                                             T+ B+ NK+, ↓IgM, ↓IgA
  PID 55       7y                        M            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                  URI                                                                                                                        GASTROENTERITIS                                                                                                                       T+ (↑CD8), B+, NK+, ↓IgM, ↓IgG, ↓IgA
  PID 56       14y                       F            CVID                                     ION TORRENT PANEL 1-2-3                                             *CTLA4 + PTEN*                                       URI                                                                                                                                                                                                                                                              T+ (↑CM, ↑THF, ↓TREG) B+ (↑NAIVE, ↓SWITCHED MEMORY, ↑AUTOREACTIVE B cells) NK+, ↓IgA
  PID 57       1y                        M            CVID                                     HALOPLEX PANEL 2                                                    TNFRSF13B[^\*^](#TN1){ref-type="table-fn"}+ *TCF3*   URI                                                                                                                        NON-SPECIFIC COLITIS, NF1                                                                                                             T+ (↑CD4 CM), B+, NK+, ↓IgM, ↓IgG, ↓IgA
  PID 58       1y                        M            CVID                                     ION TORRENT PANEL 1/HALOPLEX PANEL 2                                TNFRSF13B[^\*^](#TN1){ref-type="table-fn"}+ *TCF3*   URI                                                                                                                        NON-SPECIFIC COLITIS, NF1, ARTHITIS                                                                                                   T+ (↑CD4 CM), B+, NK+, ↓IgM, ↓IgG, ↓IgA
  PID 59       5y                        M            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                  CHRONIC EBV VIREMIA, PNEUMONIA                                                                                                                                                                                                                                   T+ (↑γδ) B+,NK+, ↓IgA
  PID 60       12y                       F            CVID                                     HALOPLEX PANEL 2                                                                                                         CHRONIC EBV VIREMIA, URI, PNEUMONIA, WARTS                                                                                                                                                                                                                       T+, ↓B, NK+, ↓IgA
  PID 61       9mo                       M            CVID                                     HALOPLEX PANEL 2                                                    *TNFRSF13B[^\*^](#TN1){ref-type="table-fn"}*         URI, LRI, HHV6                                                                                                             GASTROENTERITIS,ESSENTIAL ARTERIAL HYPERTENSION, ARNOLD-CHIARI SYNDROME TYPE I, GLICOSURIA, PSYCHOMOTOR DELAY                         T+, B+(↓ SWITCHED MEMORY) NK+, ↓IgA
  PID 62       2y                        M            CVID                                     HALOPLEX PANEL 2                                                                                                                                                                                                                                    CHRONIC DIARRHEA, GASTROENTERITIS                                                                                                     T+ B+ (↑IgM MEMORY), NK+, HYPOGAMMAGLOBULINEMIA
  PID 63       2y                        M            CVID                                     HALOPLEX PANEL 2                                                                                                         UTI, LTI                                                                                                                   MILD NEURODEVELOPMENTAL DELAY; DYSGENESIS OF THE CORPUS CALLOSUM; ARACHNOID CYST, MILD THROMBOCYTOPENIA                               T+, LOW B, NK+ ↓IgM, ↓IgA
  PID 64       11y                       M            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                                                                                                                                                                                                                                                                                   T+ (↑CD4 CM), B+(LOW SWITCHED MEMORY), NK+, ↓IgM, ↓IgG, ↓IgA
  PID 65       2y                        F            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                  UTI, LTI (PNEUMOCOCCUS),                                                                                                   ECZEMATOUS DERMATITIS; GENERALIZED LYMPHADENOPATHY; HEPATOSPLENOMEGALY, GLILD                                                         T+ (↓NAIVE CD4, ↑ EM CD8), B+(ABSENT MEMORY), NK+, ↓IgM, ↓IgG, ↓IgA
  PID 66       3mo                       F            CVID                                     ION TORRENT PANEL 1-2-3                                                                                                  URI; LRI; SEPSI                                                                                                            CANDIDA ENTERITIS,MALFORMATIVE SYNDROME, PSYCHOMOTOR RETARDATION, CHDs;CGH ARRAY: 15q25.1 DUPLICATION                                 T+ (↑EMRA CD4), B+, NK+, ↓IgM, ↓IgA
  PID 67       15y                       M            CVID                                     HALOPLEX PANEL 1                                                                                                         SALMONELLA OSTEOMIELYTIS                                                                                                   LINFOADENOPATHY, SPLENOMEGALY, AHA„ITP                                                                                                T+, B+, NK+, HYPOGAMMAGLOBULINEMIA
  PID 68       6y                        M            CVID                                     HALOPLEX PANEL 2                                                                                                                                                                                                                                    LINFOADENOPATHY, SPLENOMEGALY, AHA, ITP, PULMONARY INFILTRATES, BRONCHIECTASIS                                                        T+, B+, NK+, IgA-, IgG-
  PID 69       1y                        M            CVID                                     HALOPLEX PANEL 2                                                                                                         RECURRENT VZV, RECURRENT INFECTIONS                                                                                        URTICARIA, ANGIOEDEMA, LUNG FIBROSIS                                                                                                  T+, B+, NK+, IgA ↓, IgG ↓
  PID 70       15y                       M            CVID                                     HALOPLEX PANEL 2                                                    *TNFRSF13B*                                          RECURRENT INFECTIONS                                                                                                       LINFOADENOPATHY, SPLENOMEGALY,HYPOTHYROIDISM, LUNG NODULAR INFILTRATES, GROUND GLASS                                                  T+, B+, NK+, IgM ↓
  PID 71       12y                       F            CVID                                     HALOPLEX PANEL 2                                                                                                         RECURRENT PNEUMONIA                                                                                                                                                                                                                                              T+, B+, NK+, HIPER IgG
  PID 72       13y                       M            CVID                                     HALOPLEX PANEL 1                                                                                                                                                                                                                                    PULMONARY NODULES                                                                                                                     T+, B+, NK+, IgG-, IgM-, IgA-
  PID 73       10y                       M            SELECTIVE IgM DEFICIENCY                 ION TORRENT PANEL 1-2-3                                                                                                  SEPSI; URI, LRI                                                                                                            GASTROENTERITIS; HEPATOSPLENOMEGALY                                                                                                   T+ (↑γδ), B+ ↓ MEMORY), NK+, ↓IgM
  PID 74       12y                       F            HYPERIGG4                                HALOPLEX PANEL 2                                                                                                                                                                                                                                                                                                                                                                          T+, B+, NK+, ↑IgG4
  PID 75       2y                        M            UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY   ION TORRENT PANEL 1-2-3                                             *TCF3*                                               ATYPICAL MYCOBACTERIOSIS (M.AVIUM)                                                                                         BRONCHIAL GRANULOMA                                                                                                                   T+ (↑CD4), B+, ↓NK+, ↓IgA
  PID 76       5y                        M            UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY   ION TORRENT PANEL 1-3/HALOPLEX PANEL 2                                                                                   CHRONIC HHV-6 VIREMIA, URI; PNEUMONIA; MOLLUSCUM CONTAGIOSUM                                                               DERMATITIS                                                                                                                            T+ (↑NAIVE CD4, ↑LATE EFFETOR CD8, ↓THF, ↓TREG) B+ (↓MEMORY, ↑TRANSITIONAL), NK+
  PID 77       6y                        F            UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY   ION TORRENT PANEL 1-2-3/ HALOPLEX PANEL 2                           *NOD2*                                               CHRONIC CMV AND HHV-6 VIREMIA                                                                                              BURKITT LYMPHOMA, EBV-REACTIVATION, CMV PRIMARY INFECTION                                                                             T+ (LOW NAIVE CD8), B+ (LOW MEMORY), ↑IgM, ↓IgG, ↓IgA
  PID 78       12y                       M            UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY   ION TORRENT PANEL 1-2-3/HALOPLEX PANEL 2                                                                                 CHRONIC EBV VIREMIA                                                                                                        THROMBOCYTOPENIA; GASTROENTERITIS                                                                                                     T+, B+ (↓ IgM MEMORY AND ↓SWITCHED MEMORY), NK+, ↓IgM, ↓IgA
  PID 79       3y                        M            UNCLASSIFIED SYNDROMIC DEFICIENCY        ION TORRENT PANEL 1-2-3                                                                                                                                                                                                                             THROMBOCYTOPENIA IMMUNOMEDIATED, CELIAC DISEASE                                                                                       T+, B+, NK+, ↓IgA
  PID 80       6y                        F            IMMUNE DYSREGULATION                     ION TORRENT PANEL 1                                                                                                      URI, LRI, RECURRENT SKIN INFECTIONS                                                                                        DERMATITIS, FEMORAL DYSPLASIA                                                                                                         T+ (↑NAIVE CD4), B+ (↓ MEMORY) , NK+
  PID 81       10y                       M            IMMUNE DYSREGULATION                     ION TORRENT PANEL 1-3/HALOPLEX PANEL 2                              *AIRE[^\*^](#TN1){ref-type="table-fn"}+ PLCG2*       URI                                                                                                                        ALOPECIA; ONYCHODYSTROPHY                                                                                                             T+, ↓B+, NK+, ↓IgG, ↓IgA
  PID 82       2y                        F            INNATE IMMUNE DISEASE                    ION TORRENT PANEL 1-2/HALOPLEX PANEL 1      ***MYD88/CARD9***                                                            CHRONIC EBV, HHV-6, CMV VIRMEMIA, URI; UTI; PBI                                                                            INGUINAL ABSCESS; GRANULOMATOUS LYMPHADENITIS                                                                                         T+ B+ NK+
  PID 83       3y                        M            NEUTROPENIA                              HALOPLEX PANEL 2                            ***JAGN1***                                                                  CHRONIC EBV VIREMIA, LRI,URI                                                                                               APHTOSIS                                                                                                                              T+, B+ (↓ IgM MEMORY and ↓SWITCHED MEMORY), NK+, ↑IgA
  PID 84       1y                        F            NEUTROPENIA                              HALOPLEX PANEL 2                            ***CECR1***                                                                  RECURRENT INFECTIONS                                                                                                       SEVERE NEUTROPENIA                                                                                                                    T+, B+, NK+, NEUTROPENIA
  PID 85       5y                        F            NEUTROPENIA                              HALOPLEX PANEL 2                                                                                                                                                                                                                                    CARDIOPATHY, NEUTROPENIA, NEUROLOGICAL DELAY, LIGAMENT LAXITY                                                                         T+, B+, NK+, NEUTROPENIA
  PID 86       13d                       M            ALPS-LIKE                                HALOPLEX PANEL 1                            ***NRAS***                                                                   URI                                                                                                                        THROMBOCYTOPENIA; SPLENOMEGALY                                                                                                        T+ (↑CD4 CM, ↓RTE, ↑CD8 EM and ↑EMRA), B+(↓SWITCHED MEMORY), NK+
  PID 87       3y                        M            ALPS                                     HALOPLEX PANEL 2                                                    *TNFRSF13B*                                          GENITAL AND PERIANAL WARTS, TONSILLITIS, PNEUMONIA                                                                         AHA, ITP, LINFOADENOPATHY, SPLENOMEGALY, HYPOGAMMAGLOBULINEMIA, PULMONARY INFILTRATES                                                 T+, B+, NK+, ↓IgG, IgM-, ↓IgA
  PID 88       8y                        M            VEO-IBD                                  ION TORRENT PANEL 1                         ***XIAP***                                                                   CHRONIC EBV AND HVV-6 VIREMIA, URI                                                                                         ENTEROPATHY                                                                                                                           T+, B- (↑CD8 EM and ↑EMRA), NK+
  PID 89       4y                        M            VEO-IBD                                  ION TORRENT PANEL 1                                                                                                      CHRONIC EBV VIREMIA                                                                                                        ENTEROPATHY; CELIAC SPRUE                                                                                                             ↓T+, ↑B+, NK+
  PID 90       2y                        M            VEO-IBD                                  ION TORRENT PANEL 1-2/HALOPLEX PANEL 2                                                                                   CHRONIC VZV VIREMIA, URI                                                                                                   CHRONIC DIARRHEA, CELIAC SPRUE                                                                                                        T+ (↓NAIVE CD4) B+ NK+
  PID 91       2mo                       M            AUTOINFLAMMATORY SYNDROME                ION TORRENT PANEL 1-2                                                                                                    HLH; HEPATOSPLENOMEGALY; SKIN RASH; SYSTEMIC INFLAMMATORY SYNDROME                                                         CHRONIC DIARRHEA, MONOCYTOPENIA                                                                                                       T+ (↑CM CD4+ ↓ RTE), B+ (↑SWITCHED MEMORY B CELL, ↑PLASMABLAST ↑CD21LOW, ↓TRANSITIONAL B CELL), AND DC-
  PID 92       13y                       F            AUTOINFLAMMATORY SYNDROME                HALOPLEX PANEL 2                                                                                                                                                                                                                                    SLE                                                                                                                                   T+, B+, NK+
  PID 93       5y                        F            UNCLASSIFIED SYNDROMIC DEFICIENCY        ION TORRENT PANEL 1-2                                                                                                    CHRONIC EBV VIREMIA, URI, PNEUMONIA                                                                                        CHRONIC BRONCOPNEUNOPATY, MALFORMATIVE SYNDROME PSYCHOMOTOR DELAY                                                                     T+ (↑CM CD4+ ↑THF), B+ (↓ IgM MEMORY and ↓SWITCHED MEMORY), ↓ NK
  PID 94       1y                        M            UNCLASSIFIED SYNDROMIC DEFICIENCY        ION TORRENT PANEL 1-2                                                                                                    CHRONIC EBV VIREMIA                                                                                                        LAMBERT EATON SYNDROME, GLIOMA, 5q- MYELODISPLASIA; PSYCHOMOTOR RETARDATION; POLYNEUROPATHY                                           T+ ↓B NK+
  PID 95       1.5y                      M            UNCLASSIFIED SYNDROMIC DEFICIENCY        HALOPLEX PANEL 1                                                    *BMP4*                                               URI, LRI                                                                                                                   THROMBOCYTOPENIA, HYPERLAXITY, DENTAL ANOMALIES; DYSMORPHIC FEATURES; CRYPTORCHIDISM; SEVERE MYOPIA; ECTODERMAL DYSPALSIA SIGNS       T+, B+, NK+
  PID 96       9y                        M            SYNDROMIC                                ION TORRENT PANEL 1-2                                                                                                    URI, POLYALLERGY                                                                                                           INTERSTITIAL TUBULOPATHY; CHRONIC PANCREATITIS; CHRONIC GASTRODUODENITIS; MILD ESOPHAGITIS; BRONCOPNEUMOPATHY WITH BRONCHIECTASIAS.   T+ (↑CM CD4+ ↓ RTE), B+, NK+
  PID 97       4y                        M            SYNDROMIC                                ION TORRENT PANEL 1                                                                                                                                                                                                                                 HYPOSURRENALISM; COATS DISEASE; MYELODYSPLASIA; HYPOSPADIAS; MONOSOMY CHR 7                                                           T+ (↑ CD4+), ↓B (↓TRANSITIONAL and ↑PLASMACELLS, NK+,↑IgA
  PID 98       2y                        M            ACUTE LIVER FAILURE                      ION TORRENT PANEL 1-2                                                                                                    CHRONIC EBV VIREMIA, TWO EPISODES OF ACUTE EPATITIS                                                                        GROWTH RETARDATION, IUGR                                                                                                              T(↑ CD4+), B+, ↓NK+
  PID 99       4y                        M            HYPERSENSITIVITY                         ION TORRENT PANEL 1                                                                                                      LTI (RECURRENT BRONCHITIS), ORAL PAPILLOMATOSIS, ATOPIC DERMATITIS                                                         FOOD ALLERGY                                                                                                                          T+ (↑γδ), B+, NK+
  PID 100      16y                       F            IMMUNE DYSREGULATION                     HALOPLEX PANEL 1                                                                                                         RECURRENT INFECTIONS                                                                                                       ENTEROCOLITIS                                                                                                                         T+, B+, NK+
  PID 101      7y                        F            IMMUNE DYSREGULATION                     HALOPLEX PANEL 2                                                                                                         WARTS, NAIL FUNGAL INFECTION (NOT RECURRENT)                                                                               ALOPECIA, AUTOIMMUNE THYROIDITIS, MILD LYMPHOPENIA                                                                                    ↓T, B+, NK+
  PID 102      na                        M            OTHER (TROMBOCYTOPENIC PURPURA)          ION TORRENT PANEL 1-2                                                                                                                                                                                                                               HYPOSPADIAS, ITP                                                                                                                      T+ (↑CM CD4+), B+, NK+
  PID 103      11y                       M            OTHER                                    HALOPLEX PANEL 2                                                                                                                                                                                                                                    ALOPECIA                                                                                                                              T+, B+, NK+
  PID 104      13y                       M            OTHER                                    HALOPLEX PANEL 2                                                                                                                                                                                                                                    ITP                                                                                                                                   T+, B+, NK+, ↓IgG, ↓IgA
  PID 105      4y                        F            OTHER                                    HALOPLEX PANEL 2                                                                                                                                                                                                                                    AUTOIMMUNE/AUTOINFLAMMATORY PHENOTYPE                                                                                                 

*EBV, Epstein-Barr; CMV, Cytomegalovirus; VZV, Varicella-Zoster Virus; HHV-6, Human Herpesvirus 6; HPV, Human Papilloma Virus; URI, Upper Respiratory Infection; LRI, Lower Respiratory Infections; UTI, Urinary Tract Infection; SLE, Systemic Lupus Erythematosus; ITP, Idiopathic Thrombocytopenic Purpura; HLH, Hemophagocytic Lymphohistiocytosis; AIHA, Autoimmune Haemolytic Anemia; CHDs, Congenital Heart Disease ; NF1, Neurofibromatosis 1. ↓ low as compared to age matched normal range; ↑high as compared to age matched normal range*.

Black Bold: Ion Torrent diagnosis. Blue Bold: Haloplex diagnosis. Different colors show genes in which we found: Violet

*\> Previous Sanger detections in predisposing gene variants to PID; Violet \> predisposing gene variants to PID. Gray \> no-causative disease variants; Green \> variants of uncertain significance (VUS). Orange \> variant in genes partially associated to the clinical phenotype*.

Ion Torrent Target System
-------------------------

### Panel Design

The construction of targeted panels design required the study of several reported clinical phenotypes of known PID genes described in the IUIS (International Union of Immunological Societies) in the years 2014--2015. Our three custom Ion Torrent panels were designed with Ampliseq Designer software using GRCh37 (panel 1 and 2) and GRCh38 (panel 3) as references. Primers were divided into two pools. The first custom panel (panel 1) contains 17 known genes related to SCID-CID phenotypes (85.85 kb). The second custom panel (panel 2) includes 24 genes for less frequent CID phenotypes (101.9 kb) and the third panel (panel 3) includes 62 genes for CVID (240.01 kb) ([Supplementary Tables S1](#SM4){ref-type="supplementary-material"}--[S3](#SM6){ref-type="supplementary-material"}). The final design was expected to cover 95.43% of the first panel, 94.13% of the second panel and 97.2% of the third genes panel. For each gene included in the panels a 10 bp of exon padding was included to cover the flanking regions of exon\'s coding sequences (CDS) including (panel 1 and 2) or not (panel 3) the untranslated regions (UTRs).

### Ion Torrent Gene Target Library Preparation and NGS Sequencing

DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen). Five nanograms of gDNA were used for library preparation. DNA was amplified with 17 amplification cycles using gene panel Primer Pools and AmpliSeq HiFi mix (Thermo Fisher). PCR pools for each sample were combined and subjected to primer digestion with FuPa reagent (Thermo Fisher). Libraries were indexed using the Ion Xpress Barcode Adapter Kit. After purification, the amplified libraries were quantified with Qubit® 2.0 Fluorometer. All samples were diluted at a final concentration of 100 pM, then amplicon libraries were pooled for emulsion PCR (ePCR) on an Ion OneTouch System 2TM using the Ion PGM Template OT2 200 kit or Ion Chef according to manufacturer\'s instructions. Quality control of all libraries was performed on Qubit® 2.0 Fluorometer. Ampliseq Design Samples were subjected to the standard ion PGM 200 Sequencing v2 protocol using Ion 316 v2 chips or Ion S5 using Ion 520 v2 chips (Life Technologies).

### Ion Torrent Bioinformatics Analysis, Variants Filtering, and Assessment of Pathogenicity

Mapping and variants calling were performed using the Ion Torrent suite software v3.6. Sequencing reads were aligned on GRCh37 (panel 1 and 2) and GRCh38 (panel 3) reference genome using the program distributed within the Torrent mapping Alignment Program (TMAP) map4 algorithm (Thermo Fisher; <https://github.com/Ion> Torrent/TS). The alignment step is limited only to the regions of target genes. BAM files with aligned reads were processed for variant calling by Torrent Suite Variant Caller TVC program and variants in Variant Calling Format (VCF) file were annotated with ANNOVAR. Called variants with minimum coverage of 30X, standard Mapping Quality and Base Phred Quality were examined on Integrative Genome Viewer (IGV) and BIOMART. Filtering procedures selected variants with a minor allele frequency (MAF) \< 2% annotated using the following public databases: 1000 Genomes Project (2500 samples; <http://www.1000genomes.org/>), the Exome Variant Server (ESP) (6500 WES samples; <http://evs.gs.washington.edu/EVS/>) and the Exome Aggregation Consortium (ExAC) (60,706 samples; <http://exac.broadinstitute.org/>). Nonsense, frame-shift, start lost, stop lost, and canonical splice site variants were considered potentially pathogenic ([@B6]). *In silico* prediction of functional consequences of novel SNV was performed using Mutation taster, LTR, Polyphen2, SIFT, and CADD score \>15 ([@B26]--[@B30]) and literature available data. [Supplementary Figure 1A](#SM1){ref-type="supplementary-material"} summarizes all steps of the process.

Haloplex Target System
----------------------

### Panel Design

We designed *two* panels including up to 300 known PID genes ([@B3]) chosen from a Custom Gene Target Panel from Agilent SureDesign online tool (<http://web16.kazusa.or.jp/rapid_original/>) and about 300 candidate additional genes taken from the RAPID web site (<http://rapid.rcai.riken.jp>) from the RIKEN Center for Integrative Medical Science, from the literature and the ESID Online Registry. The candidate genes category includes genes that might be found in clinically relevant PID pathways and can share similar biological function of known PID genes. The first panel of 623 target genes comprised 7,245 regions with 66,600 amplicons, while the second panel of 601 target genes, included 6,984 regions and 73,061 amplicons. The designed probes capture 25 flanking bases in the coding exons regions ([Supplementary Tables 4A,B](#SM7){ref-type="supplementary-material"}). The final probe design was expected to cover \>97% of target regions. Practical coverage is indicated.

### Haloplex Gene Target Library Preparation and NGS Sequencing

Genomic DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen) and quantified by Qubit dsDNA BR Assay Kit (Thermofisher). DNA integrity was check by agarose gel (1% of agarose in TAE 1x). Genomic DNA was enriched with Haloplex Target Enrichment System kit (Agilent Technologies Inc., 2013, Waghäusel-Wiesental, Germany). Libraries were prepared according to the manufacturer\'s instructions. Briefly, 225 ng of genomic DNA was enzymatically digested; fragments were hybridized with conjugated biotin probes for 16 h at 54°C. Circularized target DNA-Haloplex probe hybrids were captured with streptavidin-coated magnetic beads. DNA ligase was added to the capture reaction to close nicks in the circularized probe-target DNA hybrids. All DNA samples were individually indexed during the hybridization step and library PCR amplification was performed on the Mastercycler Nexus Thermal Cyclers (Life Sciences Biotechnology, Hamburg, Germany). Amplicons were purified with AMPure XP beads (Beckman Coulter, Inc., Krefeld, Germany). Sequencing was performed with a MiSeq Reagent Kit v3 (600 Cycles) with 7 pM of sample libraries loaded on the Illumina MiSeq (San Diego, CA, USA). Quality controls after fragmentation and final concentration of prepared libraries, were assessed by Bioanalyzer (Agilent Technologies Inc., Eindhoven, the Netherlands).

### Haloplex Bioinformatics Analysis, Variants Filtering, and Assessment of Pathogenicity

FastQ files were aligned to the human reference genome (UCSC hg19, GRCh37) by Burrows--Wheeler Aligner ([@B31]). Picard HsMetrics was applied to analyze the target-capture sequencing experiments (<http://picard.sourceforge.net/>) and internal scripts were used to calculate mean gene coverage. Variant calling was performed by Freebayes ([@B32]). Raw variants were filtered by the following parameters: QUAL\> 1, (QUAL/AO)\> 10, SAF\> 0, SAR \> 0, RPR \> 1, RPL \> 1. Variants with an allele depth below 20 reads were excluded from the analysis. Selected variants were annotated for dbSNP-146, ClinVar, dbNSFP v2.9 databases and SnpEff ([@B33]) and were filtered for Common Allele Frequencies (CAF) \< 5% and variant effect on exons (missense, frameshift, splice acceptor/donor, start lost, stop lost, stop gained, 3′UTR, 5′UTR). Variants found in the either 5′ or 3′ UTR were excluded from the subsequent analyses. *In silico* analysis for variants\' pathogenicity was determined according to 5 prediction tools: Mutation taster, LTR, Polyphen2, SIFT, and CADD score \>15 ([@B26]--[@B30]). In case of trios, variants were subdivided according to model of inheritance (Autosomal Recessive/Dominant, X-linked, *De novo*). The complete bioinformatics analysis is reported in [Supplementary Figure 1B](#SM1){ref-type="supplementary-material"}.

Statistical Analysis
--------------------

Data were analyzed with Graph-Pad Prism, version 6.2 (Graph Pad Software, la Jolla, CA).

Results {#s3}
=======

Characterization of PID Patients
--------------------------------

In this study, we report the clinical and molecular characterization of 105 PID patients presenting with either typical or overlapping PID phenotypes. Patients were clustered according to initial clinical presentation in 3 main categories ([Figure 1A](#F1){ref-type="fig"}): *T-cell defects* (including Omenn syndrome, SCID, CID, syndromic T-cell defect, unclassified T-cell deficiency, hyper IgM syndrome); *Humoral defects* (agammaglobulinemia, CVID, unclassified antibody deficiency, dysgammaglobulinemia); *Other PIDs* (immune dysregulation, innate immunity defects including congenital defects of phagocytes, syndromic defects with immune-deficiency signs/symptoms, ALPS-ALPS-like, autoinflammatory syndrome, and a miscellaneous that includes non-typical PID patients with a broad range of clinical phenotypes). The clinical, immunological, and molecular features are reported in [Table 1](#T1){ref-type="table"}. The percentage of patients in each subgroup is shown in [Figures 1B--D](#F1){ref-type="fig"}. Among the *T-cell defects* (*n* = 50; 47,7%), the majority of patients presented with SCID (48%), followed by CID (32%) ([Figure 1B](#F1){ref-type="fig"}). The *Humoral Defects* group (*n* = 28; 26,6%) was mainly represented by CVID (75%), while the *Other PIDs* group (*n* = 27; 25,7%) included a wide spectrum of rare defects and uncommon phenotypes.

![Clinical diagnosis of patients at admission. **(A)** Percentage of patients for three main categories. Percentage of each clinical diagnosis in patients belonging to **(B)** *T cell defects*, **(C)** *Humoral defects* and **(D)** *Other PIDs* categories. For each category the total number of patients is indicated.](fimmu-10-00316-g0001){#F1}

Seventy-three PID patients were analyzed by Ion Torrent sequencing system using three different panels including SCID/CID and CVID known genes. Two Haloplex panels including more than 600 known and candidate PID genes were applied to 32 additional patients. Additionally, 18 patients previously analyzed by Ion Torrent but still without a clear molecular diagnosis, were analyzed by Haloplex system. A flow chart showing the *route map* for sequencing of index patients is shown in [Figure 2](#F2){ref-type="fig"}.

![Flowchart indicating the strategy of the study. ([@B1]) Indicates the only patient in *Humoral defect* group who has been analyzed by Ion Torrent panel 1.](fimmu-10-00316-g0002){#F2}

Target Enrichment Performance and Gene Coverage
-----------------------------------------------

The mean target coverage resulted of 529 ± 169X (panel 1), 361 ± 97X (panel 2) and 417 ± 117X (panel 3) for Ion Torrent and 229 ± 25X for Haloplex panels ([Supplementary Figure 2A](#SM2){ref-type="supplementary-material"}). The mean target coverage for Ion Torrent panels was optimal as compared to recently published works in which a coverage of 335X was obtained ([@B34]). Indeed, the Ion Torrent expected coverage of the coding regions was 95.43% for panel 1 (SCID-CID), 94.13% for panel 2 (rare CID) and 97.2% for the panel 3 ([Supplementary Tables 1](#SM4){ref-type="supplementary-material"}--[3](#SM6){ref-type="supplementary-material"}). The practical coverage obtained from Ion Torrent panels is shown in [Supplementary Figures 2B--D](#SM2){ref-type="supplementary-material"}.

Primer design for Haloplex aimed at covering more than 97% of the coding regions for all genes. The observed coverage of the targeted regions after running the two panels is represented in [Supplementary Tables 4A,B](#SM7){ref-type="supplementary-material"}. The majority of shared genes included in all panels and analyzed by both technologies were well-covered ([Supplementary Figures 3A--C](#SM3){ref-type="supplementary-material"}).

Performance Evaluation
----------------------

The use of large panels for NGS retrieved a big number of data as compared to small panels. Putative variants detected by Ion Torrent have been examined and validated obtaining an average of false positive variants \< 0.6%. Such value decreases reducing the number of genes included in the panel. Haloplex produces larger amount of variants, but only the ones significantly indicative among those related to the patient\'s phenotype have been investigated; hence, we could not properly evaluate data accuracy. In the 18 patients resequenced by Haloplex, no variants in genes included in the Ion Torrent panels were found supporting the accuracy of these methods. Furthermore, 6 available samples previously diagnosed by Sanger sequencing with 8 known different mutations in *RAG1, IL2RG, JAK3*, and *LIG4* genes, were included in the study and detected by Ion Torrent panel 1 ([Table 2A](#T2){ref-type="table"}).

###### 

Genetic mutations in 6 positive control PID patients.

  **ID**    **Disease**   **Gene**   **RefSeq**     **Mutation**                      **dbSNP and references**                  **Zygosity**                **Method**              **OMIM**      
  --------- ------------- ---------- -------------- --------------------------------- ----------------------------------------- --------------------------- ----------------------- ------------- -----------------
  PID I     OS            *RAG1*     NM_000448      a\) c.1682G\>A; p.R561H           b\) c.1871G\>A; p.R624H                   rs104894284; rs199474680    Compound Heterozygous   Ion Torrent   OMIM ^\*^179615
  PID II    SCID          *IL2RG*    NM_000206      a\) c.452T\>C; p.L151P                                                      rs137852511                 Hemizygous              Ion Torrent   OMIM ^\*^308380
  PID III   SCID          *JAK3*     NM_000215      **a) c.1208G\>A; p.R403H**                                                  Scarselli et al. ([@B35])   Homozygous              Ion Torrent   OMIM ^\*^600173
  PID IV    SCID          *LIG4*     NM_001352601   a\) c.833G\>A, p.R278H            b\) c.1271_1275delAAAGA; p.K424RfsTer20   Cifaldi et al. ([@B36])     Compound Heterozygous   Ion Torrent   OMIM ^\*^601837
  PID V     leaky SCID    *RAG1*     NM_000448      a\) c.2521C\>T; p.R841W                                                     rs104894287                 Homozygous              Ion Torrent   OMIM ^\*^179615
  PID VI    leaky SCID    *RAG1*     NM_000448      a\) c.256_257del; p.K86VfsTer33                                             rs772962160                 Homozygous              Ion Torrent   OMIM ^\*^179615

*In bold novel mutations*.

One false negative diagnosis has been recently recognized. Indeed, the Torrent Suite Variant Caller TVC program was unable to identify the c.C664T: p.R222C mutation in exon 5 of IL2RG gene in patient PID16 but this was detectable on IGV.

Molecular Diagnoses
-------------------

In our cohort, 28.6% (30/105) of molecular diagnosis was obtained ([Figure 3A](#F3){ref-type="fig"}). Sanger sequencing for all mutations and parents\' carrier status were performed. Functional studies were conducted for most novel variants and results are reported in [Table 2B](#T3){ref-type="table"}.

![Comparison between different number of genetic diagnoses obtained by Ion Torrent and Haloplex. **(A)** Histogram showing the number of overall *diagnosed* (red), *under investigation* (orange) or *undiagnosed* (gray) patients. **(B)** Histogram showing the Ion Torrent diagnoses. **(C)** Histograms showing Haloplex diagnoses. **(D)** Diagnostic findings by Haloplex in negative Ion Torrent patients. The percentages refer only to diagnosed patients.](fimmu-10-00316-g0003){#F3}

###### 

Mutations detected in our PID cohort.

  **ID**   **Disease**             **Gene**   **RefSeq**     **Mutation**                       **dbSNP and references**             **Zygosity**                             **Inheritance**         **Method**     **OMIM**                **Functional test**   
  -------- ----------------------- ---------- -------------- ---------------------------------- ------------------------------------ ---------------------------------------- ----------------------- -------------- ----------------------- --------------------- --------------------------------
  PID 1    OS                      *RAG1*     NM_000448      a\) c.1870C\>T; p.R624C            b\) c.2521C\>T; p.R841W              rs199474688; rs104894287                 Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^179615       
  PID 2    SCID                    *RAG2*     NM_000536      a\) c.685C\>T; p.R229W                                                  rs765298019                              Homozygous              Unknown        Ion Torrent             OMIM ^\*^179616       
  PID 3    SCID                    *RAG2*     NM_000536      **a) c.1A\>G; p.M1V**              b\) c.1403_1406del ATCT              n.d.; rs786205616                        Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^179616       n.a.
  PID 4    SCID                    *RAG1*     NM_000448      a\) c.1681C\>T; p.R561C            **b) c.1815G\>C; p.M605I**           rs104894285; Dobbs et al. ([@B37])       Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^179615       Recombinase activity ongoing
  PID 5    SCID                    *IL2RG*    NM_000206      a\) c.202G\>A; p.E68K                                                   rs.1057520644                            Hemizygous              Familial       Ion Torrent             OMIM ^\*^308380       
  PID 6    SCID                    *JAK3*     NM_000215      **a) c1796T\>G; p.V599G**          b\) c.2125T\>A; p.W709R              Di Matteo et al. ([@B38]); rs748216175   Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^600173       Published data
  PID 12   SCID                    *ADA*      NM_000022      **a) c. 455T\>C p.L152P**          b\) c.478+6T\>C                      n.d.; Santisteban et al. ([@B39])        Compound Heterozygous   Familial       Ion Torrent/Haloplex    OMIM ^\*^608958       Reduced ADA enzymatic activity
  PID 15   SCID                    *ADA*      NM_000022      **a) c.367delG; p.D123fsTer10**                                         n.d.                                     Homozygous              Familial       Ion Torrent             OMIM ^\*^608958       Reduced ADA enzymatic activity
  PID 16   CID                     *IL2RG*    NM_000206      a\) c.C664T:p.R222C                                                     rs111033618                              Hemizygous              De novo        Ion Torrent             OMIM ^\*^308380       
  PID 17   SCID                    *IL2RG*    NM_000206      a\) c.677G\>A; p.R226H                                                  rs869320660                              Hemizygous              Familial       Ion Torrent             OMIM ^\*^308380       
  PID 18   SCID                    *IL2RG*    NM_000206      a\) c.854G\>A; (splice)                                                 rs111033617                              Hemizygous              Familial       Ion Torrent             OMIM ^\*^308380       
  PID 19   SCID                    *IL2RG*    NM_000206      **a) c.455T\>G; p.V152G**                                               n.d.                                     Hemizygous              Familial       Ion Torrent             OMIM ^\*^308380       n.a.
  PID 20   SCID                    *RAG1*     NM_000448      a\) c.1229G\>A; p.R410Q            **b) c.1863delG; p.A622QfsTer9**     rs199474684; n.d.                        Compound Heterozygous   Unknown        Ion Torrent             OMIM ^\*^609889       n.a.
  PID 21   SCID                    *CD3D*     NM_000732      a\) c.274+5G\>A                                                         rs730880296                              Homozygous              Mother; n.a.   Ion Torrent             OMIM ^\*^186790       
  PID 22   SCID                    *RAG1*     NM_000448      **a) c.987delC: p.S330LfsTer15**                                        n.d.                                     Homozygous              Unknown        Ion Torrent             OMIM ^\*^179615       Evident pathogenicity
  PID 23   SCID                    *JAK3*     NM_000215      a\) c.308G\>A; p.R103H                                                  rs774202259                              Homozygous              Unknown        Ion Torrent             OMIM ^\*^600173       
  PID 24   SCID                    *JAK3*     NM_000215      a\) c.1132G\>C; p.G378R            b\) c.1442-2A\>G                     rs1485406844; JAK3base_D0095             Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^600173       
  PID 25   SCID                    *IL7R*     NM_002185      **a) c.134A\>C; p.Q45P**           b\) c.537+1G\>A                      n.d.; rs777878144                        Compound Heterozygous   Familial       Haloplex                OMIM ^\*^146661       n.a.
  PID 29   CID                     *RAG1*     NM_000448      a\) c. 2521C\>T; p.R841W                                                rs104894287                              Homozygous              Familial       Ion Torrent             OMIM ^\*^179615       
  PID 31   CID                     *RAG1*     NM_000448      a\) c.1871G\>A; p.R624H            **b) c. 1213A\>G; p.R405G**          rs199474680; n.d.                        Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^179615       Recombinase activity ongoing
  PID 36   CID                     *IL7R*     NM_002185      **a) c.160T\>C; p.S54P**           **b) c.245G\>T; p.C82F**             rs1002396899; rs757797163                Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^146661       
  PID 37   CID                     *ARPC1B*   NM_005720      **a) c.64+1G\>A**                                                       Brigida et al. ([@B40]) (accepted)       Homozygous              Familial       Haloplex                OMIM ^\*^604223       Published data
  PID 39   CID                     *RAG1*     NM_000448      **a) c.2119G\>C; p.E665D**         b\) c.519delT ; p.Glu174SerfsTer27   n.d.; rs1241698978                       Compound Heterozygous   Unknown        Haloplex                OMIM ^\*^179615       n.a.
  PID 49   HIGM                    *CD40LG*   NM_000074      a\) c.410-2 A\>T                                                        rs1254732497                             Hemizygous              Familial       Ion Torrent             OMIM ^\*^300386       
  PID 51   CVID                    *RAG1*     NM_000448      a\) c.1871G\>A; p.R624H            **b) c.2182T\>C; p.Y728H**           rs199474680; Cifaldi et al. ([@B41])     Compound Heterozygous   Familial       Ion Torrent             OMIM ^\*^179615       Published data
  PID 88   IBD                     *XIAP*     NM_001167      **a) c.566T\>C; p.L189P**                                               Cifaldi et al. ([@B42])                  Hemizygous              De novo        Ion Torrent             OMIM ^\*^300079       Published data
  PID 83   NEUTROPENIA             *JAGN1*    NM_032492      a\) c.63G\>T; p.E21D                                                    rs587777729                              Homozygous              Familial       Haloplex                OMIM ^\*^616012       
  PID 84   NEUTROPENIA             *CECR1*    NM_001282225   **a)c.1367A\>G, p.Y456C**          **b)c.1196G\>A, p.W399^\*^**         Barzaghi et al. ([@B43])                 Compound Heterozygous   Familial       Haloplex                OMIM ^\*^607575       Accepted for publication
  PID 82   INNATE IMMUNE DISEASE   *CARD9*    NM_052813      a\) c.1434+1G\>C                   Chiriaco et al. ([@B44])             rs141992399                              Homozygous              Familial       Ion Torrent/ Haloplex   OMIM ^\*^607212       
                                   *MYD88*    NM_002468      a\) c.195_197delGGA; p.E66del                                           rs878852993                              Homozygous              Familial                               OMIM ^\*^602170       
  PID 86   ALPS-LIKE               *NRAS*     NM_002524      a\) c.35G\>A; p.G12D                                                    rs121913237                              Heterozygous            Somatic        Haloplex                OMIM ^\*^164790       

In bold novel not described mutations

A rapid molecular diagnosis was established in 30.1% (22/73) of PID patients who were investigated by Ion Torrent. Diagnoses were achieved in *RAG1, RAG2, IL2RG, JAK3, ADA, CD3D, IL7R, CD40L*, and *XIAP* genes (see [Table 2B](#T3){ref-type="table"}). As expected, the identification of a molecular defect resulted more frequent in patients with a clear clinical and immunological phenotype as shown in those included in the group of *T cell defects* (20/42; 47.6%) ([Figure 3B](#F3){ref-type="fig"}). Interestingly, the percentage of diagnosis in the group of SCID/CID patients was 60.6% (20/33).

The percentage of molecular diagnosis for the 50 patients studied through the Haloplex panels was of 16% (8/50) as shown in [Figure 3A](#F3){ref-type="fig"}. The first 6 diagnoses were obtained in a cohort of 32 patients. Three SCID/CID patients with mutations in RAG1, IL7R and ARPC1B genes \[([@B40], [@B45]--[@B47]) and Volpi et al., under revision\] were diagnosed in 8 *T cell defects* (37,5%). Moreover, *JAGN1* ([@B48])*, CECR1* ([@B43]) and *NRAS* genes, associated to complex phenotypes, were identified in 12 of the *Other PIDs* group (25%) ([Figure 3C](#F3){ref-type="fig"}).

Two additional patients were diagnosed analyzing the 18 patients, previously negative by Ion Torrent, presenting with a less defined immunological phenotype ([Figure 3D](#F3){ref-type="fig"}). For one patient (PID12), the Ion Torrent panel 1 was able to detect only a missense mutation in the *ADA* gene. Haloplex identified the second intronic mutation located in the fifth nucleotide upstream exon 5, not included in the Ion Torrent design, of the gene. In the second Ion Torrent negative patient (PID82) presenting an atypical HyperIgE syndrome, Haloplex detected two rare homozygous mutations in *MYD88* and *CARD9* genes, which were not included in the Ion Torrent panels (1 and 2). The pathogenic role of each single gene mutation is still under investigation but this molecular information is important to optimize the clinical management of the patient including the evaluation of HSCT as definitive treatment ([@B44]).

In summary, 4 SCID/CID patients out of a total of 16 *T cell defects*, were identified by Haloplex, demonstrating once more a higher percentage of diagnosis in this PID group ([Table 2B](#T3){ref-type="table"}). However, although the possibility to identify a causative gene mutation correlates with a precise clinical clusterization, the identification of patients, with complex and extended phenotypes, needs larger NGS panels.

Disease-Associated Variants
---------------------------

Comparing the results obtained by the two methods, 44 (32 Ion Torrent and 12 Haloplex) disease-associated variants have been identified in 30 patients, of whom 18 were novel ([Table 2B](#T3){ref-type="table"}). The majority of variants detected by Ion Torrent were missense (*n* = 23; 74.2%) as summarized in [Figure 4A](#F4){ref-type="fig"}. We were also able to detect 4 small deletions and 5 splice site variants. The Haloplex panels detected 5 missense, 2 deletions, 4 splice site and 1 stop codon variants ([Figure 4B](#F4){ref-type="fig"}). Among the 30 diagnosed patients, we found 13 compound heterozygous patients with mutations in *RAG1, JAK3, ADA, IL7R*, and *CECR1* genes, 9 homozygous variants including *ADA, RAG1, RAG2, CD3D, JAK3, ARPC1B, MYD88/CARD9*, and *JAGN1*, 7 hemizygous variants in *IL2RG, CD40LG*, and *XIAP*, and only 1 heterozygous somatic variant in *NRAS* ([Figure 4C](#F4){ref-type="fig"}). Therefore, most patients enrolled in this study were offspring of non-consanguineous marriages. The most frequent mutated gene in our cohort is *RAG1* followed by *IL2RG* ([Figure 4D](#F4){ref-type="fig"}).

![Type and zygosity of mutations and mutated genes distribution. Types and percentage of mutations found in diagnosed PID patients for Ion Torrent **(A)** and Haloplex **(B)**. **(C)** Overall observed zygosity for diagnosed PID patients. **(D)** Total number of detected mutated genes.](fimmu-10-00316-g0004){#F4}

Putative Neutral Variants vs. Variants of Uncertain Significance (VUS)
----------------------------------------------------------------------

Fifteen CVID patients were initially analyzed by Ion Torrent panels 1-2, but no causative variants were found. We therefore designed a specific CVID panel and found 4 putative causative variants suggestive of AD disease that was confirmed by Sanger sequencing. Indeed, we found a heterozygous damaging variant in the *CTLA4* gene and a predicted damaging variant in the *PTEN* gene in an adult patient followed since childhood (PID56). The patient inherited one mutation from the father and one from the mother but the real role of these variants and their possible combined effect is still under investigation. In addition, two other VUS in *TCF3* and *PLCG2* genes were found in two patients (PID75 and PID54), in which no other evidences are available (see [Table 1](#T1){ref-type="table"}).

A rare variant in *CD40L* gene (p.R200S) found in patient PID50 was excluded from the analysis, although an altered CD40L expression was detected. This variant was predicted benign in multiple databases. Furthermore, a homozygous rare variant in *CECR1* gene (p.Q233R) was found in patient PID13. However, the two proband\'s healthy brothers were found to be homozygous for this variant thus it was not considered pathogenic, nevertheless, additional functional studies will be performed to exclude genetic predisposition (e.g., ADA2 activity, protein expression).

Three novel variants of uncertain significance (VUS) identified by Haloplex in patients with classical and complex phenotypes are still "under investigation." We are currently validating a novel damaging variant in the *TCF3* gene in two twin patients (PID57-58) and their mother affected by CVID ([@B49]). EMSA assay is ongoing to assess the capacity of TCF3 protein to bind DNA target sequences. In these twin patients we also previously found by Sanger sequencing a mutation in TNFRSF13B gene already described to be associated to CVID ([@B50]).

A causative variant in the *BMP4* gene ([@B51]) with a severe myopia, ectodermal dysplasia, and cytopenia was found in a patient (PID95) in whom the altered immunological phenotype remains poorly explained by this mutation. Moreover, *NF*κ*B1* variant in a CID patient (PID38) was found but its significance is still under investigation.

Finally, heterozygous variants in *TNFRSF13B* (PID70, PID87) and *NOD2* (PID77), genes were found by Haloplex in three patients. Generally, variants in susceptibility genes involved in the disease pathogenesis should be considered for potential future phenotypic implications particularly in adult patients where multiple factors may contribute to the onset of the disease.

Discussion {#s4}
==========

The application of multigene NGS panels has extended our knowledge of PIDs and is currently recognized as a comprehensive diagnostic method in the field of rare disorders consenting the diagnosis in the 15--70% of all cases depending on the PID clinical and phenotypic clusterization ([@B25], [@B52]). In the present work we show that the complementary, integrated use of two custom-made targeted sequencing approaches, Ion Torrent or Haloplex, allowed to clearly identify causative variants in 28.6% (*n* = 30) of the patients in all groups of PIDs, confirming the value of NGS assays to obtain a genetic diagnosis for PIDs ([@B17]--[@B23]).

The Ion Torrent approach resulted highly successful for SCID patients, a group generally more defined for its immunological and clinical presentation ([@B53]). Indeed, with this approach we identified 20/33 SCID/CID patients (60,6%). The Haloplex workflow was able to identify causative variants in 8/50 patients (16%) of whom 4 were found in the group of SCID/CID patients and 4 fall in that of complex and extended phenotypes. Interestingly, a molecular diagnosis was achieved in 2/18 (11%) patients presenting with typical and atypical clinical phenotypes resulted negative after Ion Torrent analysis and included in the Haloplex approach.

By NGS it is possible to identify unexpected mutations in apparently not corresponding PID cases, as recently reported by our group for a patient with agammaglobulinemia due to *RAG1* deficiency ([@B41]). This result strengthen the notion of a large phenotypic variety associated with RAG deficiency, suggesting that it should be considered also in patients presenting with an isolated marked B-cell defect ([@B54]--[@B57]) and as already reported that RAG mutations are more frequent than expected. Notably, RAG1 is the most frequent PID cause in our cohort. This case represents a paradigmatic model of how new questions arise on the management and follow-up for patients in which a milder phenotype could be associated to alternative treatments to transplantation ([@B41], [@B57], [@B58]).

CVID is a typical example of a disease with a broad phenotype due to different gene alterations ([@B59]--[@B61]). Notably, in 4 CVID patients with mutations in *TNFRSF13B* and *AIRE* previously detected by Sanger sequencing (see [Table 1](#T1){ref-type="table"}) we extended NGS analysis to looking for novel disease causing genes. Therefore, frequent variants comparable to polymorphisms should be considered with caution since the pathogenic meaning is still unclear. Additional functional studies in these cases are required. Four additional diagnoses are summarized in [Supplementary Table 5](#SM8){ref-type="supplementary-material"} ([@B62]). These were obtained after the completion of the present study by other targeted NGS panels and Sanger sequencing, indicating that the combination of in-depth clinical knowledge and appropriate sequencing techniques can lead to new diagnoses.

Although the prioritization methods applied in this study follows all common assumptions for a correct data analysis, the identification of novel variants currently under investigation represents a challenge and their validation needs the essential support of further in-depth experimental studies ([@B6]--[@B8], [@B63]). The integration of clinical, immunological, biochemical and molecular data might favor a revised PIDs classification of patients with similar phenotype due to a different genetic cause, or patients with different phenotypes but with the same genetic cause. In our experience, the use of selected NGS panels is useful and easy to handle for rapid diagnosis in clinically and immunologically well-characterized phenotypes. As compared to WES, targeted small NGS panels provide an important alternative for clinicians for direct sequencing of relevant genes, guaranteeing a high coverage and sequencing depth ([@B64]). On the contrary, their application in patients with atypical phenotypes could result in an incomplete and delayed diagnosis. Extended gene panels or WES should be directly used in these cases for research purposes, to allow the diagnosis of unexpected genotype-phenotype association.

As reported by several groups ([@B7], [@B8], [@B22]--[@B24]), the application of targeted WES for each suspicion of PID by exploring gene-by-gene also for limited numbers of striking genes still remain time and resource consuming in the absence of synergy between clinical and bioinformatics supports. This is yet unfeasible for extended diagnostic purposes. Indeed, the huge amount of retrieved data and the risk of incidental findings in other non-PID genes involved in different monogenic or multifactorial pathologies may be confounding and do not corresponding to the first suspicion. Additionally, the confidence of the results decreases with the number of targeted genes and may preclude any variant detection in self-evident known genes ([@B65]). Many previously undetected variants do not have a well-defined role in our genome (1.5 × 10^6^ million variants in each genome and lesser in exome). In this scenario, ethical and legal issues related to the disclosure of genetic information generated by NGS need to be considered and guidelines should be developed to help the different specialists to translate the genetic results into the clinics ([@B64]).

The achievement of NGS application will require further integration of knowledge based on clinical, immunological and molecular data and the collaboration among different experts in these fields. A better clinical, immunological and genetic characterization of new PIDs will significantly contribute to the identification of diagnostic and prognostic markers and early individual therapeutic strategies with significant patients\' benefit.
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Schematic representation of filtering variants strategy for Ion Torrent **(A)** and Haloplex **(B)**.
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###### 

Coverage analysis. **(A)** Mean target coverage for genes included in Haloplex and Ion Torrent panels 1-2 and 3. Box and whiskers show median, 5th and 95th percentiles. Haloplex shows 605 shared genes in the two panels. **(B)** Mean gene coverage for Ion Torrent Panel 1, **(C)** panel 2 and **(D)** panel 3. Coverage is shown as number of reads.
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Comparison of coverage analysis. **(A--C)** Comparison of mean gene coverage in shared genes between Ion Torrent and Haloplex panels.
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Theoretical coverage of genes included in Ion Torrent panel 1.
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Theoretical coverage of genes included in Ion Torrent panel 2.
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Theoretical coverage of genes included in Ion Torrent panel 3.
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**(A)** Theoretical and effective coverage of gene intervals in Haloplex platform panel 1. **(B)** Theoretical and effective coverage of gene intervals in Haloplex platform panel 2.
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Additional diagnoses obtained after this study.
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AD

:   Autosomal Dominant

AR

:   Autosomal Recessive

CAF

:   Common Allele Frequency

CDS

:   Coding Sequence

CID

:   Combined Immunodeficiencies

CVID

:   Common Variable Immunodeficiency

IGV

:   Integrative Genome Viewer

MAF

:   Minor Allele Frequency

NGS

:   Next Generation Sequencing

PCR

:   Polymerase Chain Reaction

PID

:   Primary Immunodeficiency

SCID

:   Severe Combined Immunodeficiency

SNP

:   Single Nucleotide Polymorphism

UTR

:   Untranslated Region

VCF

:   Variant Calling Format

WES

:   Whole Exome Sequencing

WGS

:   Whole Genome Sequencing.
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